Application of esketamine in anesthesia of children undergoing colonic transendoscopic enteral tubing

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069541

Enrollment

Unknown

Registered

2023-03-20

Start date

2022-12-30

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Procedural sedation and analgesia in Children with Autism Spectrum Disorder

Interventions

eskatemine(S group):eskatemine 0.30 mg/kg + propofol 2mg/kg

sufentanil(SF group):sufentanil 0.2ug/kg + propofol 2mg/kg

Eligibility

Sex/Gender

All

Age

2 Years to 12 Years

Inclusion criteria

Inclusion criteria: (1)aged 2–12 years (2)American Society of Anesthesiologists (ASA) physical status I–III (3) diagnosed with autism spectrum disorder by DSM

Exclusion criteria

Exclusion criteria: (1)Oral sedation before intravenous injection (preoperative);(2)any contraindication to study medications;(3) and other circumstances in which the investigator determined that a patient was not suitable for participation in the clinical trial.(4) Parents refused to participate in the study.

Design outcomes

Primary

Measure	Time frame
heart rate;blood pressure;number of body movements;	—

Secondary

Measure	Time frame
additional dosage of propofol;	—

Countries

China

Contacts

Public ContactMiao Yanxiang

Sir Run Run Hospital, Nanjing Medical University

570660433@qq.com17368464006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026